Shcell
International cell therapy center
Shcell, founded in November, 2013 and headquartered in Shanghai, is an international cell therapy complex platform company. Established by Li Jiewei, the company has received financings from Haier Capital, Volcanics Capital, Yao Ji Poker and so on. Rivals that have direct and indirect competition with Shcell globally include Cell Medica, etc.
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ForLong Biotech Nets Over CNY 100 Mn in Series A
4 Chinese Immunotherapy Companies to Keeps Tabs on in 2019
Four Chinese pharmaceuticals are developing promising cancer immunotherapy drugs. Along with the advantageous policies and unmet needs within China's healthcare ecosystem, they will presumably shine for patients and investors in 2019.
May 15, 2019 02:34 PM
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Levostar Completes Pre-A Financing Round to Further Invest in CGT
BlissBio Nets Over CNY 100 Mn in Series B+
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
NaviSeed Nets Tens of millions of CNY in Angel Round
Nuwacell Nets Hundreds of Mns of CNY in Series A
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Biotech in China: Oasis in the Desert?
Following AstraZeneca's USD 1 billion-large capital injection plans with China's state-backed CICC, and I-Mab Biopharma's long-anticipated IPO, all eyes are back on China's lucrative Biotech scene. EqualOcean sums up the story.
Nov 12, 2019 06:02 PM
Enitiatebio Nets One Hundred Million of CNY in Series A Round
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange